Chronicle Journal: Finance

Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
AbbVie (NY: ABBV)
87.84 USD  -0.89 (-1.00%)
Official Closing Price  /  Updated: 7:52 PM EST, Dec 13, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 5,976,000
Open 88.78
Bid (Size) 87.50 (1)
Ask (Size) 88.25 (5)
Prev. Close 88.73
Today's Range 87.33 - 89.09
52wk Range 62.66 - 92.99
Shares Outstanding 1,586,879,451
Dividend Yield 4.09%
Performance
YTD
-1.56%
-1.56%
1 Month
+1.36%
+1.36%
3 Month
+24.58%
+24.58%
6 Month
+11.63%
+11.63%
1 Year
+0.15%
+0.15%
Top News
More News
Cancer Drug Revenues Expected to be Largest Share in Pharma Market
category Featured News
from FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Cancer Drug Revenues Expected to be Largest Share in Pharma Market
Financialnewsmedia.com News Commentary Read More
from PR Newswire
More News
Read More
Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay
from GlobeNewswire News Releases
AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics
from PR Newswire
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Ly
from PR Newswire
More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unr
from PR Newswire
Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)
from PR Newswire
Abbvie Inc Shares Up 25.8% Since SmarTrend's Buy Recommendation (ABBV)
from Comtex SmarTrend® News Briefs
UPDATE 2-Biogen scraps development of therapy for rare brain disease
category companyNews
from Reuters: Company News
UPDATE 1-Biogen scraps development of therapy for rare brain disease
category companyNews
from Reuters: Company News
Noteworthy Thursday Option Activity: MAS, ABBV, C
category Stocks
from Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]